
Literature Review: Diagnosing Types of Dementia Using Biomarkers Haley Jahnke PA-S, Hanna Maxwell PA-S, Brett Bastian PA-C

Physician Assistant Graduate Program, Northwestern College

Introduction¹

Diagnosing types of dementia early in the disease process is necessary in creating management strategies such as early planning, determining the cause, beginning treatment as soon as possible, and identifying and treating other associated symptoms.



Symptoms can be similar among different types of dementia, and some people have more than one form of dementia, which can make an accurate diagnosis difficult. Symptoms can also vary from person to person. Doctors may ask for a medical history, complete a physical exam, and order neurological and laboratory tests to help diagnose dementia.

Treatment

There is currently no cure for these types of dementia, but some treatments are available. Speak with your doctor to find

What is a Biomarker?³

Biomarker: "A measurable and quantifiable biological parameter that serves as an indicator of a particular physiological state. In a medical context, a biomarker is a substance whose detection indicates a particular disease state or a response to a therapeutic intervention."

Research Question

In patients presenting with dementia-like symptoms, what biomarkers are effective to use to diagnose the most common types of dementia?

Biomarkers

Alzheimer's Disease4,5,6,7,8

- ↑ P-tau & t-tau
- ↑ GFAP, CHIT1, YKL-40
- ↑ Glutamic acid, hypoxanthine, anthranilic acid

Frontotemporal Dementia^{4,5,7,9,10}

- ↓ P-tau & t-tau
- ↑ AB42/40
- ↑ GFAP, CHIT1, YKL-40
- △ NPTX2 & neurofilament light chain
- MRI anterior vs. posterior index

Vascular Dementia^{11,12}

- Brevican & neurocan peptides: VaD < AD
- ↑ MR-proANP, CT-proET-1

Lewy Body Dementia^{13,6}

CSF α -synuclein: LBD << AD

↑ GFAP

REPS1 has been identified as a hub gene in both Alzheimer's disease and vascular dementia. Further research is required to determined if it can be used to distinguish between those types.

Conclusion

Understanding the specific biomarkers for each type of dementia is crucial in establishing an early and definitive diagnosis that can determine the appropriate course of treatment. Each of the biomarkers outlined in this literature review vary in their clinical applicability. Although some of them have already been incorporated into clinical practice alongside manifestations and symptoms characteristic to each type of dementia, others still require further research and studies before they are put to use. Some of these biomarkers are specific in their ability to distinguish between dementia types, while a few others reflect general disease processes seen in more than one type.

- 2. Understanding Different types of Dementia. National Institute on Aging.
- https://www.nia.nih.gov/health/infographics/understanding-different-types-dementia
- 3. Hartmann D. biomarker. Encyclopedia Britannica. https://www.britannica.com/science/biomarker Published December 7, 2018
- Skillbäck T, Farahmand BY, Rosén C, et al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with
- dementia. Brain: A Journal of Neurology. 2015;138(Pt 9):2716-2731. doi:10.1093/brain/awv181

 5. Rostgaard N, Waldemar G, Nielsen JE, Simonsen AH. Cerebrospinal Fluid Biomarkers in Familial Forms
- of Alzheimer's Disease and Frontotemporal Dementia, Dementia and Geriatric Cognitive Disorders 2015:40(1-2):54-62. doi:10.1159/000381828
- 6. Chouliaras L. Thomas A. Malpetti M. et al. Differential levels of plasma biomarkers of
- neurodegeneration in lewy body dementia, alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. Journal of Neurology, Neurosurgery & Psychiatry. 2022;93(6):651-658. doi:10.1136/jnnp-2021-327788
- 7. Abu-Rumeileh S, Steinacker P, Polischi B, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research & Therapy. 2019;12(1). doi:10.1186/s13195-019-0562-4
- 8. Chouraki V, Preis SR, Yang Q, et al. Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. Alzheimer's & Dementia: The Journal of the Alzheimer Association, 2017:13(12):1327-1336, doi:10.1016/j.jalz.2017.04.009
- 9. Van der Ende E.L., Bron EE, Poos JM, et al. A data-driven disease progression model of fluid biomarker in genetic frontotemporal dementia. Brain: A Journal of Neurology. 2022;145(5):1805-1817. doi:
- 10. Bruun M, Koikkalainen J, Rhodius-Meester HFM, et al. Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage: Clinical. 2019;22. doi:10.1016/j.nicl.2019.101711
- 11. Minta K, Brinkmalm G, Portelius E, et al. Brevican and Neurocan Peptides as Potential Cerebrospina Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2021;79(2);729-741, doi:10.3233/jad-201039
- 12. Holm H. Nägga K. Nilsson ED, et al. Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study. *Journal of Internal Medicine*. 2017;282(1):94
 101. doi:10.1111/joim.12621
- 13. Lilamand M, Clery J, Vrillon A, et al. Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation Between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice. International Journal of Molecular Sciences. 2022;23(21):13488. Published 2022 Nov 4. doi:10.3390/ijms232113488
- 14. Luo J. Chen L. Huang X. et al. REPS1 as a Potential Biomarker in Alzheimer's Disease and Vasculai Dementia. Frontiers in Aging Neuroscience. 2022. doi: https://doi.org/10.3389/fnagi.2022.89482

Future Directions¹⁴

Living with dementia can be challenging, but there are ways to manage it. To learn more about these types of dementia and other conditions that can cause dementia, visit

Between 45 and 64

